On Jul. 9, 2020, Royal Philips announced it had formed a strategic collaboration with BioIntelliSense, a continuous health monitoring and clinical intelligence company, to integrate its BioSticker medical device into Philips’ remote patient monitoring (RPM) offering to help monitor at-risk patients from the hospital into the home. Philips’ solutions can enhance how clinicians monitor patient populations living with chronic conditions – including diabetes, cancer, congestive heart failure and more – in their homes with passive monitoring of key vital signs, physiological biometrics and symptomatic events via a discreet wearable patch for monitoring up to 30 days.

Remote patient monitoring and telehealth-enabled clinical programs offer care teams a sustainable and scalable way to manage patient populations with chronic or complex conditions at home, and plays a key role in supporting care for COVID-19 patients who do not require hospitalization. By regularly transmitting patient data that can provide critical insights into a patient’s condition, the collaboration will empower care teams in the U.S. with a more holistic patient view and the ability to intervene earlier before adverse events occur. With single-use sensors and patient-owned technology supporting remote monitoring, care teams can also help reduce the need for clinicians and patients to interact in person.

The BioSticker is a single-use, FDA-cleared 510k class II wearable medical device to enable at-home continuous passive monitoring with minute level data across a broad set of vital signs, physiological biometrics and symptomatic events (skin temperature, resting heart rate, resting respiratory rate, body position, activity levels, cough frequency) on a single device for thirty-days. Symptoms, including those directly associated with COVID-19 such as temperature and respiratory rate, can be remotely monitored in confirmed cases of Coronavirus and also for those patients not sick enough to be hospitalized, or those suspected of having COVID-19. In addition to COVID-19, the BioSticker device will help transform the way clinicians monitor and manage patients living with chronic conditions from the home.

Tags: